<b>Background/Objectives:</b> Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular benefits beyond glycemic control, yet the specific biological pathways potentially linking SGLT2 inhibitor exposure to cardiovascular outcomes after acute myocardial infarction (AMI) remain incompletely characterized. This evidence concerns the gene SLC5A2 and acute myocardial infarction.